Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: Results from the danish nationwide DANBIO registry

Arthritis and Rheumatism

Volumn 65, Issue 5, 2013, Pages 1213-1223

  Glintborg, Bente ^a   Østergaard, Mikkel ^b,i   Krogh, Niels Steen ^c   Andersen, Martin Dehn ^d   Tarp, Ulrik ^e   Loft, Anne Gitte ^f   Lindegaard, Hanne M ^g   Holland Fischer, Mette ^e,h   Nordin, Henrik ⁱ   Jensen, Dorte Vendelbo ^b,j   Olsen, Christian Holkmann ^d   Hetland, Merete Lund ^a,i  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c Zitelab Aps   (Denmark)

^d FREDERIKSBERG HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f LILLEBAELT HOSPITAL   (Denmark)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h AALBORG UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j Nordsjællands Hospital Hillerød   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REGISTER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COHORT STUDIES; DENMARK; DRUG SUBSTITUTION; FEMALE; HEALTH STATUS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; REGISTRIES; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876572244     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37876     Document Type: Article

References (53)

1. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12.
2. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94.
3. Mease PJ,. Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol 2009; 21: 348-55.
4. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012; 71: 319-26.
5. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72.
6. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-89.
7. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ,. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
8. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al, for the IMPACT 2 Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-7.
9. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34: 1040-50.
10. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005; 52: 1227-36.
11. Saad AA, Symmons DP, Noyce PR, Ashcroft DM,. Risks and benefits of tumor necrosis factor-α inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008; 35: 883-90.
12. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study [published erratum appears in Arthritis Rheum 2010;62:2555]. Arthritis Rheum 2009; 60: 976-86.
13. Pitarch G, Sanchez-Carazo JL, Mahiques L, Oliver V,. Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 2008; 216: 312-6.
14. Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 2008; 67: 717-9.
15. Mazzotta A, Esposito M, Costanzo A, Chimenti S,. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 2009; 10: 319-24.
16. Gomez-Reino JJ, Carmona L,. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006; 8: R29.
17. Chakravarty EF, Reed G, Decktor G, Bolge S, Bolce R, Ingham M, et al. TNF switching in PsA patients [abstract]. Arthritis Rheum 2010; 62 Suppl: S820.
18. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP,. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11: R52.
19. DANBIO. Danish Rheumatological Database. URL: https://danbio-online.dk.
20. Glintborg B, Ostergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382-90.
21. Hetland ML, Unkerskov J, Ravn T, Friis M, Tarp U, Andersen LS, et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice: first results from the Danish Database (DANBIO). Scand J Rheumatol 2005; 34: 40-4.
22. Hetland ML, Lindegaard HM, Hansen A, Podenphant J, Unkerskov J, Ringsdal VS, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008; 67: 1023-6.
23. Hetland ML,. DANBIO-powerful research database and electronic patient record. Rheumatology (Oxford) 2011; 50: 69-77.
24. Schefte DB, Hetland ML,. An open-source, self-explanatory touch screen in routine care: validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index, Function Index, the Health Assessment Questionnaire and Visual Analogue Scales in comparison with paper versions. Rheumatology (Oxford) 2010; 49: 99-104.
25. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
26. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
27. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A,. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
28. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
29. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A,. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 1694-8.
30. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
31. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
32. Haberhauer G, Strehblow C, Fasching P,. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr 2010; 160: 220-4.
33. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF,. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005; 34: 353-8.
34. Hjardem E, Ostergaard M, Podenphant J, Tarp U, Andersen LS, Bing J, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor α inhibitor? Ann Rheum Dis 2007; 66: 1184-9.
35. Glintborg B, Ostergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2012. E-pub ahead of print.
36. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML,. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69: 2002-8.
37. Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-α blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011; 13: R94.
38. Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008; 59: 234-40.
39. Hyrich KL, Watson KD, Silman AJ, Symmons DP,. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
40. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study. Arthritis Res Ther 2009; 11: R7.
41. Wallis D, Jadon D, Tillett W, Waldron N, Cavill C, McHugh N, et al. Psoriatic arthritis and biologic therapy: treatment response, drug survival and outcome after switching-an observational study [abstract]. Ann Rheum Dis 2012; 71 Suppl 3: iii691.
42. Carmona L, Gomez-Reino JJ,. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8: R72.
43. Gratacos J, Casado E, Real J, Torre-Alonso JC,. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007; 66: 493-7.
44. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.
45. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995; 38: 38-43.
46. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006; 65: 1373-8.
47. Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2005; 32: 2262-9.
48. Dougados M,. It's good to feel better but it's better to feel good [editorial]. J Rheumatol 2005; 32: 1-2.
49. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011; 70: 272-7.
50. Coates LC, Mumtaz A, Helliwell PS, Mease PJ, Callis-Duffin K, Krueger GG, et al. Development of a disease severity and responder index for psoriatic arthritis (PsA)-report of the OMERACT 10 PsA special interest group. J Rheumatol 2011; 38: 1496-501.
51. Fernandez-Sueiro JL,. The challenge and need of defining axial psoriatic arthritis. J Rheumatol 2009; 36: 2633-4.
52. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al, STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007; 147: W163-94.
53. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies [published erratum appears in Ann Intern Med 2008;148:168]. Ann Intern Med 2007; 147: 573-7.